Image for Antineoplastons
Antineoplastons

Synonyms/Common Names/Related Substances:

  • 3-N-phenylacetylaminopiperidine-2,6 dione, 3-phenylacetylamino-2,6-piperidinedione, A1, A2, A3, A4, A5, A10, A10-1, AS2-1, AS2-5, AS5, Antineoplaston A, Antineoplaston Ch, Antineoplaston F, Antineoplaston H, Antineoplaston K, Antineoplaston L, Antineoplaston O, phenylacetic acid (PAA), phenylacetylglutamine (PAG), phenylacetylisoglutamine (PAIG), sodium phenylacetate.

Clinical Bottom Line/Effectiveness

Brief Background:

  • Antineoplastons are a group of naturally occurring peptide fractions, which were observed by Stanislaw Burzynski, MD, PhD, in Houston, Texas in the late 1970s, to be absent in the urine of cancer patients. It was hypothesized that these substances may have antitumor properties. In the 1980s, Burzynski identified chemical structures for several of these antineoplastons, and developed a process to prepare them synthetically. Antineoplaston A10, identified as 3-phenylacetylamino-2,6-piperidinedione, was the first to be synthesized.
  • Antineoplastons are agents that are both naturally occurring and synthetically produced based on peptide fragments isolated from the blood and urine of healthy individuals. It is theorized that antineoplastons act by inducing differentiation in neoplastic cells. Antineoplastons are also believed to inhibit DNA synthesis and mitosis of neoplastic cells.
  • Antineoplastons with a broad spectrum of activity include: A1, A2, A3, A4, A5, A10, A10-1, AS2-1, AS2-5 and AS5 (1). Antineoplaston A is a mixture of all of the latter antineoplastons. Those with selective activity against just one of each type of neoplasm include: Antineoplastons H, L, O, F, Ch and K (1). A10, A10-1, AS2-1 and AS2-5 are synthetic derivatives of glutamine, isoglutamine and phenylacetate (AS5) (1). Antineoplaston AS2-1 and antineoplaston AS2-5 are degradation products of antineoplaston A10.
  • The uses of antineoplastons in the treatment of various cancers have been studied in in vitro and animal studies, as well as phase I and phase II clinical trials. Antineoplaston therapy may induce weakness, drowsiness, fever, decreased platelet and white blood cell counts, nausea, vomiting, an unusual body odor and skin rash.
  • Further content available for subscribers only.

Dosing/Toxicology

  • Content available for subscribers only.

Precautions/Contraindications

  • Content available for subscribers only.

Interactions

Most herbs and supplements have not been thoroughly tested for interactions with other herbs, supplements, drugs, or foods. The interactions listed below are based on reports in scientific publications, laboratory experiments, or traditional use. You should always read product labels. If you have a medical condition, or are taking other drugs, herbs, or supplements, you should speak with a qualified healthcare provider before starting a new therapy.

  • Content available for subscribers only.

Mechanism of Action

  • Content available for subscribers only.

History

  • Content available for subscribers only.

Evidence Table

  • Content available for subscribers only.

Evidence Discussion

  • Content available for subscribers only.

Products Studied

  • Content available for subscribers only.

Author Information

  • Content available for subscribers only.

References

Natural Standard developed the above evidence-based information based on a thorough systematic review of the available scientific articles. For comprehensive information about alternative and complementary therapies on the professional level, go to www.naturalstandard.com. Selected references are listed below.

  • Content available for subscribers only.
The information in this monograph is intended for informational purposes only, and is meant to help users better understand health concerns. Information is based on review of scientific research data, historical practice patterns, and clinical experience. This information should not be interpreted as specific medical advice. Users should consult with a qualified healthcare provider for specific questions regarding therapies, diagnosis and/or health conditions, prior to making therapeutic decisions.